Rigel Appoints Michael P. Miller to the Board of Directors

"Mike has a strong track record of commercial excellence, and we're delighted to have him join our Board," said Raul Rodriguez, Rigel's president and CEO. "His extensive expertise in commercial execution and leadership will provide valuable insights as we execute on our transformational strategic plan, particularly our objectives of growing our current portfolio of medicines and evaluating potential in-licensing opportunities – areas where Mike has extensive experience."

Mr. Miller currently serves on the Board of Directors at Puma Biotechnology and BioXcel Therapeutics. He served as the Executive Vice President of U.S. Commercial of Jazz Pharmaceuticals from April 2014 until his retirement in September 2020. Before that, Mr. Miller was Senior Vice President and Chief Commercial Officer of Vivus. Prior to that, Mr. Miller served as Vice President, leading the HER Family Oncology franchise, of Genentech. Other roles included Senior Vice President, Chief Commercial Officer of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories (GSK); Vice President of the of ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson; and various sales and marketing positions at Syntex Corporation. Mr. Miller earned a B.S. in Business Administration and Finance from the University of San Francisco and an M.B.A. in Information and Computer Systems from San Francisco State University.